Immunomodulation

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, March 19, 2024
Atopic dermatitis, Head, T helper cell, HNSCC, Patient, PTCL, Lung cancer, Ipilimumab, Asthma, CTCL, ALCL, Fungal infection, Pulmonary fibrosis, Lymphocyte, RCC, Clinical trial, CRS, Marketing, B-cell lymphoma, Research, PR, PTCL-NOS, Psoriasis, T-cell lymphoma, ASH, Webcast, Immunomodulation, Pembrolizumab, PRS, Exposition, Cancer, Nivolumab, Safety, Scleroderma, Food, NSCLC, Teva Pharmaceuticals, Modified, Lymphoma, Knowledge, Allergy, Immunodeficiency, Time management, Peripheral, Poster, FDA, ITK, Conference call, Kidney cancer, T helper 17 cell, Society, Preprint, BioRxiv, Autoimmunity, Physician, Total, Pharmaceutical industry

BURLINGAME, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • ET / 1:30 p.m. PT
    BURLINGAME, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2023.
  • We have several exciting opportunities in immunology, including plans for a randomized, placebo controlled clinical trial of soquelitinib in atopic dermatitis.
  • Mr. Arcara previously served as senior vice president, head global marketing & portfolio and strategy for the innovative medicines and biosimilars business at Teva Pharmaceuticals.
  • ET (1:30 p.m. PT), during which time management will provide a business update and discuss the fourth quarter and full year 2023 financial results.

Global Anterior Uveitis (Iritis) Drug Pipeline Research Report 2024 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 6, 2024
Health, Other Science, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Therapy, Acquisition, IOP, Macrophage, News, Route, Eye, Uveitis, Discovery, Risk, Administration, Clinical trial, Immunomodulation, NDA, NCE, Pharmaceutical industry

This report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Anterior Uveitis pipeline landscape.

Key Points: 
  • This report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Anterior Uveitis pipeline landscape.
  • A detailed picture of the Anterior Uveitis pipeline landscape is provided which includes the disease overview and Anterior Uveitis treatment guidelines.
  • The assessment part of the report embraces, in depth Anterior Uveitis commercial assessment and clinical assessment of the pipeline products under development.
  • Anterior Uveitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Immunis Chairman Dr. Hans Keirstead is an Invited Speaker at the 2024 Brain Trust Conference

Retrieved on: 
Friday, February 23, 2024
Biotechnology, Pharmaceutical, Health, Therapy, Brain trust, Heart, Metabolism, Intelligence, Immunomodulation, Conference

Immunis, Inc. , a private biotech company revolutionizing cellular secretome therapeutics, is proud to announce that its Chairman, Dr. Hans Keirstead , will present at the exclusive 13D Brain Trust Conference in the Bahamas.

Key Points: 
  • Immunis, Inc. , a private biotech company revolutionizing cellular secretome therapeutics, is proud to announce that its Chairman, Dr. Hans Keirstead , will present at the exclusive 13D Brain Trust Conference in the Bahamas.
  • Brain Trust is a highly exclusive, invite-only event covering artificial intelligence, global technological advancements, innovative biotechnology, and unique investment opportunities.
  • Like its name, the Brain Trust Conference invites the world’s greatest minds to realize their visions for the world.
  • We thank the Brain Trust Conference for honoring Dr. Keirstead as a guest speaker and for including Immunis in the atmosphere of intellectual exchange to propel humanity forward.

Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases

Retrieved on: 
Monday, February 12, 2024
Atopic dermatitis, Immunodeficiency, Psoriasis, Infection, SQL, ITK, Scleroderma, Preprint, Asthma, T helper cell, Pulmonary fibrosis, T helper 17 cell, Venn, Lymphocyte, Cytokine, Rheumatoid arthritis, Immunosuppression, Dermatitis, Publication, Lymphoma, Research, Immunomodulation, Vaccine

BURLINGAME, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that preclinical data for soquelitinib, the Company’s lead ITK inhibitor program, was presented in a poster session at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases, which took place February 8-11, 2024.

Key Points: 
  • BURLINGAME, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that preclinical data for soquelitinib, the Company’s lead ITK inhibitor program, was presented in a poster session at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases, which took place February 8-11, 2024.
  • These preclinical product candidates exhibit specific biologic properties that are anticipated to enable more precise inhibition of Th1, Th2 and/or Th17 cell function.
  • Atopic dermatitis (also called eczema) and asthma are thought to be mediated primarily by Th2 lymphocytes.
  • The soquelitinib preclinical data and information on the Company’s next-generation ITK inhibitor candidates was presented by Rahul Pawar, Ph.D., Senior Scientist at Corvus, in poster session #2 (poster #2008) at the Keystone Symposia.

Inotrem Successfully Reaches Agreement with the FDA for a Phase 3 Registration Trial for Nangibotide in Septic Shock

Retrieved on: 
Monday, January 8, 2024
Biotechnology, FDA, Other Health, Health, Pharmaceutical, Biometrics, Other Science, Research, Infectious Diseases, Science, Clinical Trials, Roche, Risk, ACCURATE, Septic shock, Mortality, Disease, Blood, Incidence, Immunomodulation, Death, Intensive care medicine, Patient, Sepsis, Pharmaceutical industry

The ACCURATE trial design is built upon Phase 2 (ASTONISH) data that confirmed nangibotide’s strong efficacy and safety profile.

Key Points: 
  • The ACCURATE trial design is built upon Phase 2 (ASTONISH) data that confirmed nangibotide’s strong efficacy and safety profile.
  • This unique biomarker-guided approach allows for a single Phase 3 registration trial with a manageable number of subjects.
  • “Inotrem is now in a leading position to conduct a single Phase 3 registration trial in a prospectively defined population of septic shock patients that are at high risk of morbidity and mortality.
  • With nangibotide, Inotrem has developed a novel approach of immunomodulation targeting the TREM-1 pathway to restore appropriate inflammatory response, vascular function and improve post septic shock survival.

SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes

Retrieved on: 
Wednesday, November 29, 2023
Immunotherapy, Food, U.S. FDA, IND, Biological activity, EMA, FDA, Research, Disease, Trial of the century, MBA, MD, SAB, POBA, Pharmacokinetics, Investigational New Drug, ATG, Immunomodulation, Type 1 diabetes, Patient, Safety, CTA, Pharmaceutical industry

SIOUX FALLS, S.D., Nov. 29, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglobulin (hIgG) for disease-modification of Type 1 Diabetes (T1D) through delaying the onset and/or progression of the disease, today announced that the first participants of a HUMAN trial (Fully HUman anti-thymocyte biologic in first-in-MAN clinical study) have been dosed in Australia. This Phase 1 randomized, double-blind, placebo-controlled, single-ascending dose, adaptive design clinical study was designed to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous SAB-142 in healthy volunteers and participants with T1D. SAB-142 is a first-in-class fully-human anti-thymocyte immunoglobulin being developed as a disease-modifying treatment to delay the onset and progression of T1D.

Key Points: 
  • SAB-142 is a first-in-class fully-human anti-thymocyte immunoglobulin being developed as a disease-modifying treatment to delay the onset and progression of T1D.
  • In October 2023 , SAB received approval by the Australian Human Research Ethics Committee (HREC) to commence the Phase 1 clinical trial investigating safety, tolerability, pharmacokinetic, pharmacodynamic, and immunogenicity of SAB-142.
  • More information about the Phase 1 clinical trial with SAB-142 (ACTRN:12623001089628) can be found here .
  • “We are grateful to partner with SAB on this Phase 1 investigation that will explore the therapeutic potential of a new, potentially best-in-class immunotherapeutic option for patients.”

Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart Disease

Retrieved on: 
Sunday, November 26, 2023
DREAM, Prognosis, FDA, Endothelial dysfunction, Disease, Mortality, Person, Inflammation, Ageing, ODD, Heart, Immunomodulation, Ventricular septal defect, MSB, Growth, Patient, HLHS, Journal, Heart failure, MESO, Pharmaceutical industry

Unfortunately, achievement of this objective is limited by the inability in most patients for the left ventricle to grow sufficiently to support the circulation to the body.

Key Points: 
  • Unfortunately, achievement of this objective is limited by the inability in most patients for the left ventricle to grow sufficiently to support the circulation to the body.
  • The FDA has authority to grant orphan drug (OD) designation to a drug or biological product to prevent, diagnose or treat a rare disease or condition, defined as any disease or condition that affects less than 200,000 persons in the United States.
  • An orphan drug designation (ODD) qualifies sponsors for incentives including tax credits for qualified clinical trials, exemption from user fees, and the potential for seven years of market exclusivity after approval.
  • A rare pediatric disease designation (RPDD) demonstrates that the disease is serious or life-threatening and the manifestations primarily affect individuals aged from birth to 18 years, including age groups often called neonates, infants, children, and adolescents, and that the disease is a rare disease or condition.

NanOlogy Clinical and Preclinical Immune Data Presented at NACLC and SITC

Retrieved on: 
Tuesday, December 19, 2023
Research, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Spleen, Immunotherapy, Conference, TME, LSAM, American Conference, Flow cytometry, Blood, Mouse, Paclitaxel, Immunomodulation, Society, Poster, Safety, Lung cancer, NK, NMIBC, SITC, Vaccine

NanOlogy LLC , a clinical-stage oncology company, reports data presented as posters during recent oncology conferences.

Key Points: 
  • NanOlogy LLC , a clinical-stage oncology company, reports data presented as posters during recent oncology conferences.
  • The poster was authored by clinical investigators Hiren Mehta , Abhishek Biswas , Sarah Wang , Jason Akulian , Christine Argento , et.al.
  • Summarizing presented data:
    The early phase lung cancer trial demonstrated safety and tolerability of intratumoral (IT) LSAM-PTX in combination with various concurrent therapies, including systemic immunotherapy.
  • Summarizing presented data:
    Immunophenotyping in 3 diverse tumor settings found commonalities in antitumor immunomodulation following local LSAM-DTX, including changes in T cells and MDSCs.

IntelGenx Receives Approval to Conduct ’MONTPARK’ Montelukast VersaFilm® Phase 2 Clinical Trial in Patients with Parkinson's Disease

Retrieved on: 
Tuesday, November 14, 2023
Swedish Research Council, Leukotriene, Safety, Nations in Swedish universities, Immunomodulation, Disease, PD, Cysteinyl leukotriene receptor 1, Tablet, Patient, Karolinska University Hospital, MPA, Alzheimer's disease, United, IGX, MD, SCI, Trial of the century, Neurodegenerative disease, Doctor of Philosophy, L-DOPA, TSX, Medical Products Agency (Sweden), Pharmaceutical industry

The current standard treatment of PD motor dysfunction is based on the enhancement of dopaminergic transmission and involves the administration of L-dopa.

Key Points: 
  • The current standard treatment of PD motor dysfunction is based on the enhancement of dopaminergic transmission and involves the administration of L-dopa.
  • Early results have indicated its potential usefulness for the treatment of various neurodegenerative disorders like PD and Alzheimer’s Disease.
  • The study will enroll up to 90 patients who will receive 30 mg Montelukast VersaFilm® or placebo twice daily for 18-months, followed by a 3-month washout period.
  • 3 Wallin, J; Svenningsson, P. Potential Effects of Leukotriene Receptor Antagonist Montelukast in Treatment of Neuroinflammation in Parkinson’s Disease.

European Wellness and DXN Sign MoU to Establish World-Class Wellness Centre!

Retrieved on: 
Thursday, November 9, 2023
BWA, Health, International trade, Therapy, EW Group, Food, Myco, Heidelberg University, Research, DXN, Economic development, University, Marketing, Partnership, Plant, Immunomodulation, Hospital, KSI, Peptide, B cell, Pharmaceutical industry

CYBERJAYA, Malaysia, Nov. 9, 2023 /PRNewswire/ -- European Wellness Biomedical Group (EW Group) has signed a Memorandum of Understanding with DXN Holdings Berhad (DXN) to jointly develop and establish a comprehensive wellness centre that draws from the extensive expertise and experience of both parties.

Key Points: 
  • CYBERJAYA, Malaysia, Nov. 9, 2023 /PRNewswire/ -- European Wellness Biomedical Group (EW Group) has signed a Memorandum of Understanding with DXN Holdings Berhad (DXN) to jointly develop and establish a comprehensive wellness centre that draws from the extensive expertise and experience of both parties.
  • Their goals align with DXN, one of the most established and globalised publicly-listed Malaysian companies in researching, producing, and marketing organic health and wellness products.
  • Together, they are in pole position to revolutionise the health and wellness industry.
  • A multi-award-winning European group comprising of multinational business divisions collectively operating in the emerging fields of bio-regenerative medicine.